AZT Plus Methotrexate in HIV-Related Non-Hodgkin's Lymphomas

References

• Biggar R. J., Rabkin C. S. The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol 1992; 4: 883–893
   PubMedGoogle Scholar
• Von Gunten C. F., Von Roenn J. H. Clinical aspects of human immunodeficiency virus-related lymphoma. Curr Opin Oncol 1992; 4: 894–901
   PubMedGoogle Scholar
• Kaplan L. D., Abrams D. I., Feigal E., et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261: 719–724
   PubMed Web of Science ®Google Scholar
• Levine A. M. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992; 1: 8–20
   Google Scholar
• Raphael M. M., Andouin J., Lamine M., et al. Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Am J Clin Pathol 1994; 101: 773–779
   PubMed Web of Science ®Google Scholar
• Gill P. S., Levine A. M., Krailo M., et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987; 5: 1322–1328
   PubMed Web of Science ®Google Scholar
• Levine A. M., Sullivan-Halley J., Pike M. C., et al. Human immunodeficiency virus-related lymphoma: prognostic factors predictive of survival. Cancer 1991; 68: 2466–2471
   PubMed Web of Science ®Google Scholar
• Perkocha L. A., Rodgers G. M. Hematological aspects of human immunodeficiency virus infection: laboratory and clinical considerations. Am J Hematol 1988; 29: 94–99
   PubMed Web of Science ®Google Scholar
• Fauci A. S. The human immunodeficiency virus: inectivity and mechanisms of pathogenesis. Science 1988; 239: 617–620
   PubMed Web of Science ®Google Scholar
• Remick S. C., McSharry J. J., Wolf B. C. Novel oral chemotherapy in the treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma. J Clin Oncol 1993; 9: 1691–1697
   Google Scholar
• Tirelli U., Errante D., Oksenhendler E., et al. Prospective study with combined low-dose chemotherapy and Zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin's lymphomas. Ann Oncol 1992; 3: 843–847
   PubMed Web of Science ®Google Scholar
• Tosi P., Gherlinzoni F., Mazza P., El Al. 3′-azido 3′- deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. Blood 1997; 89: 419–425
   PubMed Web of Science ®Google Scholar
• Dournon E., Rozenbaum W., Michon C., et al. Effects of Zidovudine in 365 patients with AIDS or AIDS-related complex. Lancet 1988; II: 1297–1302
   Google Scholar
• Fischl M. A., Richmann D. D., Grieco M. H., et al. The efficacy of Azydothymidine (AZT) in the treatment of AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185–191
   PubMed Web of Science ®Google Scholar
• Furman P. A., Fyre J., Stclair M. H., et al. Phosphorylation of 3′azido 3′ deoxythymidine and selective interaction of the 5′ triphosphate with human immunodeficiency reverse trancriptase. Proc Natl Acad Sci USA 1986; 83: 8333–8337
   PubMed Web of Science ®Google Scholar
• Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3′-azido 2′-3′-dideoxythymidine (Zidovudine) and related dideoxynucleosides. N Engl J Med 1989; 321: 726–738
   PubMed Web of Science ®Google Scholar
• Horowitz J. P., Chua J., Noel M. J. Nucleoside. V. The monomesylates of 1-(2a-deoxy-b-d-lyxofuranosyl) thymines. Org Chem Ser Monogr 1964; 29: 2076
   Web of Science ®Google Scholar
• Weber G., Ichikawa S., Nagai M., Natsumeda Y. Azydothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Commun 1990; 2: 129–134
   PubMed Web of Science ®Google Scholar
• Weber G., Nagai M., Prajda N., Nakamura H., Szekeres T., Olah E. AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells. Cancer Commun 1991; 3: 127–132
   PubMed Web of Science ®Google Scholar
• Vaquez-Padua M. A., Starnes M. C., Cheng Y. C. Incorporation of 3′-azido 3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun 1990; 2: 55–62
   PubMedGoogle Scholar
• Tosi P., Visani G., Ottaviani E., Gamberi B., Cenacchi A., Tura S. Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562. Eur J Haematol 1993; 51: 209–213
   PubMed Web of Science ®Google Scholar
• Scanlon K. J., Kashani-Sabet M., Sowers L. C. Overexpression of DNA replication and repair enzymes in cysplatin-resistant human colon carcinoma HCT-8 cells and circumvention by azydothymidine. Cancer Commun 1989; 1: 269–275
   PubMedGoogle Scholar
• Brunetti I., Falcone A., Calabresi P., Goulette F. A., Darnowski J. W. 5-Fluorouracil enhances azydothymidine cytotoxicity: in vitro, in vivo and biochemical studies. Cancer Res 1990; 5: 4026–4031
   Google Scholar
• Tosi P., Calabresi P., Goulette F. A., Renaud C. A., Darnowski J. W. Azydothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro. in vivo. Cancer Res 1992; 52: 4069–4073
   PubMed Web of Science ®Google Scholar
• Frick L. W., Nelson D. J., Stclair M. H., Furman P. A., Krentisky T. A. Effects of 3′-azido-3′-deoxythymidine on the nucleoside triphosphate pools in cultured human cells. Biochem Biophys Res Commun 1988; 154: 124–129
   PubMed Web of Science ®Google Scholar
• Tosi P., Visani G., Ottaviani E., Tura S., Darnowski J. W. Hydroxyurea enhances 3′-azido-3′-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. Eur J Hematol 1994; 52: 291–295
   PubMed Web of Science ®Google Scholar
• Baselga J., Krown S. E., Telzak E. E., Filippa D. A., Straus D. J. Acquired immune deficiency syndrome- related pulmonary non-Hodgkin lymphoma regressing after Zidovudine therapy. Cancer 1993; 71: 2332–2334
   PubMed Web of Science ®Google Scholar
• Posner M. R., Darnowski J. W., Calabresi P., et al. Oral Zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase 1 study. J Natl Cancer Inst 1990; 82: 1710–1714
   PubMed Web of Science ®Google Scholar
• Posner M. R., Darnowski J. W., Weitberg A. B., et al. High-dose intravenous Zidovudine with 5-fluorouracil and leucovorin. Cancer 1992; 70: 2929–2934
   PubMed Web of Science ®Google Scholar
• Browne M. J., Beitz J., Clark J. W. A phase I study of Zidovudine (AZT) and methotrexate in patients with advanced cancer. Proc Am Soc Clin Oncol 1993; 12: 163
   Google Scholar
• Zinzani P. L., Bendandi M., Gherlinzoni F., et al. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica 1993; 78: 378–383
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Oksenhendler E., Tirelli U., et al. Human immunodeficiencyvirus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 1993; 95: 188–195
   PubMed Web of Science ®Google Scholar
• Kaplan L. D., Straus D. J., Testa M. A., et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1641–1648
   PubMed Web of Science ®Google Scholar
• Sawka C. A., Shepherd F. A., Brandwein J., Burkes R. L., Sutton D. M., Warner E. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve-week chemotherapy program. Leuk Lymphoma 1992; 8: 213–218
   PubMed Web of Science ®Google Scholar